AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7962442
Drug: Investigated for
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigated for antiphospholipid antibodies (APA), polycystic ovaries (PCO), hypersecretion of luteinizing hormone (LH), and chromosome abnormalities.
Trial: 3311439
Drug: Two-tablet regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-tablet regimen (500 mg mefloquine, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Trial: 3311439
Drug: Three-tablet regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-tablet regimen (750 mg mefloquine, 1500 mg sulfadoxine, 75 mg pyrimethamine)
Trial: 31898521
Drug: ATRA-RIF (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA-RIF (oral arsenic realgar-indigo naturalis formula)
Trial: 31898521
Drug: ATRA-ATO (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA-ATO (intravenous arsenic trioxide)
Trial: 26279077
Drug: Midazolam (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (exact dosage not specified for group M1)
Trial: 23776445
Drug: Ketamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine administration during memory testing after Pavlovian fear conditioning
Trial: 23776445
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration during memory testing after Pavlovian fear conditioning
Trial: 19450052
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral anticoagulation (e.g., warfarin or dicoumarol)
Trial: 19450052
Drug: Oral antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiplatelet agents
Trial: 11240956
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of killed Mycobacterium vaccae (SRL 172)
Trial: 11240956
Drug: Placebo (buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (buffer solution)
Trial: 9259191
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (48-hour infusion)
Trial: 9259191
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (48-hour infusion) in elderly patients (> 70 years)
Trial: 31087093
Drug: Digital behavioral
RxNorm normalized name: AspyreRx Digital Behavioral Therapeutic Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital behavioral pain medicine intervention (MSS)
Trial: 25673148
Drug: Diphenhydramine-containing medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine-containing medication (25 mg diphenhydramine, 10 mg phenylephrine)
Trial: 25673148
Drug: Dextromethorphan syrup
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan syrup (30 mg)
Trial: 24305660
Drug: Ginger patch
RxNorm normalized name: MENTHOL 2 g in 100 g / METHYL SALICYLATE 2 g in 100 g TOPICAL PATCH [Timing Pain Savior Fragrant Ginger Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger patch
Trial: 21423025
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily NVP (ExtNVP) through 14 weeks
Trial: 21423025
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily NVP + ZDV (ExtNVP/ZDV) through 14 weeks
Trial: 21423025
Drug: Control (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (single-dose nevirapine + 1-week zidovudine)
Trial: 17563161
Drug: High post
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High post acute treatment levels of decentering and low cognitive reactivity
Trial: 142248
Drug: Tilidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine (100 mg i.m.)
Trial: 142248
Drug: Pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (100 mg i.m.)
Trial: 26124508
Drug: Standard quitline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard quitline treatment
Trial: 17186000
Drug: Buspirone 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 60 mg p.o. co-administered with morphine
Trial: 17186000
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with morphine
Trial: 25046070
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg) plus montelukast (10 mg)
Trial: 15347373
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg) plus placebo
Trial: 9772141
Drug: Cooked egg
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooked egg protein (25 g of cooked 13C- and 15N-labeled egg protein)
Trial: 9772141
Drug: Raw egg
RxNorm normalized name: Egg, white, raw, fresh
DrugBank: Egg white (DB10528)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw egg protein (25 g of raw egg protein)
Trial: 1351
Drug: Visken (beta-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visken (beta-receptor blocking agent)
Trial: 30887965
Drug: Single Bond
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Bond Universal dentin bonding agent
Trial: 23644851
Drug: 7.2% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2% hypertonic saline - 6% hydroxyethyl starch (HS-HES) solution
Trial: 19934563
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) for 30 sessions (45 minutes each) at a frequency of 1 Hz and current intensity of 30 mili ampere.
Trial: 19934563
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 30 sessions (45 minutes each).
Trial: 11482341
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2x 1 g daily
Trial: 11482341
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) aiming at blood trough levels of 120-150 ng/ml
Trial: 9591815
Drug: Fluocinonide 0.05%
RxNorm normalized name: FLUOCINONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.05% cream
Trial: 31087132
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy including glucocorticoids and methotrexate
Trial: 31087132
Drug: Refractory JDM
RxNorm normalized name: Glycerin 0.14 g in 7 g TOPICAL PATCH [Mefactory Piggy Peeling Pad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refractory JDM treatments including azathioprine, ciclosporin, intravenous immune globulins, mycophenolate mofetil, and rituximab
Trial: 31087132
Drug: Validated tools
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Validated tools for assessing disease activity, disease damage, and treatment responses
Trial: 22653043
Drug: RenalGuard therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenalGuard therapy (hydration with saline and NAC controlled by the RenalGuard System and furosemide)
Trial: 22653043
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate solution and N‐acetylcysteine (NAC) (Control group)
Trial: 22653043
Drug: RenalGuard therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenalGuard therapy
Trial: 17261422
Drug: Target hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target hemoglobin level of 13 to 15 g/dL (group 1)
Trial: 17261422
Drug: Target hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target hemoglobin level of 10.5 to 11.5 g/dL (group 2)
Trial: 15297194
Drug: Concurrent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin and radiotherapy (RT)
Trial: 11260007
Drug: SDZ ASM
RxNorm normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ ASM 981 1% cream
Trial: 11260007
Drug: Betamethasone‐17‐valerate 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone‐17‐valerate 0.1% cream
Trial: 11260007
Drug: Vehicle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of SDZ ASM 981 1% cream
Trial: 9558039
Drug: 4‐Methylpyrazole (4‐MP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐Methylpyrazole (4‐MP), 15 mg/kg body weight dissolved in 50 ml of orange juice
Trial: 3243929
Drug: Tianeptine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (12.5 mg) administered after fasting
Trial: 3243929
Drug: Tianeptine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (12.5 mg) administered after a standardized breakfast
Trial: 28361616
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment plus standard medical therapy
Trial: 21336108
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg over 30 mins followed by continuous infusion of 2 μg·kg(‐1)·h(‐1) for 48 hrs)
Trial: 19858438
Drug: High social
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High social support treatment
Trial: 19858438
Drug: Low social
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low social support treatment
Trial: 15450119
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg vaginal misoprostol
Trial: 10931388
Drug: Conventional immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunotherapy (IT)
Trial: 8218956
Drug: Two products
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two products with lower bioavailability
Trial: 31574585
Drug: Relaxation intervention
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation intervention (RELAX; face‐to‐face classes and daily home practice of progressive muscle relaxation and mindfulness meditation)
Trial: 20675978
Drug: CER 15
RxNorm normalized name: Acid Reducer 150mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER 15 mg
Trial: 20675978
Drug: CER 30
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER 30 mg
Trial: 20675978
Drug: CIR 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIR 10 mg
Trial: 17405870
Drug: Assisted-control ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted-control ventilation plus volume guarantee (VG) (Vt = 5 ml/kg)
Trial: 16292641
Drug: Glutamate (1
RxNorm normalized name: Glutamate (13-N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (1 M, 0.2 ml) alone
Trial: 9365148
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg preprandial
Trial: 9365148
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg postprandial
Trial: 9365148
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg postprandial
Trial: 8466733
Drug: Slow-release isradipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release isradipine (SRO) 2.5 mg
Trial: 8466733
Drug: Slow-release isradipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release isradipine (SRO) 5 mg
Trial: 3959323
Drug: 1 liter
RxNorm normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 liter of 3% amino acid solution daily for 5 days postoperatively
Trial: 3959323
Drug: Balanced 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced 5% glucose-containing electrolyte solutions
Trial: 24375313
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (CTL)
Trial: 22210078
Drug: Sutureless amniotic
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutureless amniotic membrane patch with a modified symblepharon ring
Trial: 22210078
Drug: Conventional sutured
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sutured amniotic membrane patch
Trial: 20537750
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mix 25/75 (LM25)
Trial: 18612876
Drug: Intravenous patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient‐controlled analgesia (PCA‐IV)
Trial: 11878685
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg twice a day)
Trial: 363480
Drug: Pindolol in
RxNorm normalized name: pindolol Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol in combination with classical antihypertensives
Trial: 27991835
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (lisdexamfetamine 30, 50, or 70 mg/day)
Trial: 27991835
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (lisdexamfetamine)
Trial: 25403015
Drug: Acceptance-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavioral therapy (ABBT)
Trial: 21041570
Drug: Warfarin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0)
Trial: 21041570
Drug: Dabigatran, 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran, 110 mg twice daily (low dose)
Trial: 21041570
Drug: Dabigatran, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran, 150 mg twice daily (high dose)
Trial: 18835660
Drug: Clozapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (mean modal dose: 266.7±77.9mg)
Trial: 15520691
Drug: Incremental bite
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental bite advancement using a Twin-block appliance with 2 mm initial advancement and subsequent 2 mm advancements at 6 weekly intervals.
Trial: 7936222
Drug: Aspartame (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (approximately 30 mg/kg/d)
Trial: 2467138
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 mg adjusted to 5.0 mg and to 10.0 mg o.d.)
Trial: 2467138
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg b.i.d. titrating to 160 mg b.i.d.)
Trial: 27571237
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide gel
Trial: 30713266
Drug: 37% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% carbamide peroxide gel
Trial: 30713266
Drug: Non-thermal atmospheric
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermal atmospheric plasma treatment
Trial: 18464882
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 900 mg/day
Trial: 18464882
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 600 mg/day
Trial: 11368289
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/day plus estrogen
Trial: 11368289
Drug: Risedronate 30
RxNorm normalized name: risedronate 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 30 mg/day
Trial: 11368289
Drug: Risedronate 30
RxNorm normalized name: risedronate 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 30 mg/day for 2 months
Trial: 8188018
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms Sulprostone gel
Trial: 8188018
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Gemeprost vaginal pessary
Trial: 3276901
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (5-fluorouracil, semustine, and vincristine)
Trial: 21276244
Drug: OROS-MPH (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH (54 mg/day for 8 weeks)
Trial: 19455195
Drug: Early start
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early start dialysis (eGFR > 10 ml/min/1.73m²)
Trial: 1588370
Drug: MFL (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFL (methotrexate 250 mg/m2, fluorouracil 500 mg/m2, leucovorin rescue) for 12 courses
Trial: 1588370
Drug: Expectancy (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy (no chemotherapy until symptoms appeared)
Trial: 29747575
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) and cognitive behavioural therapy (CBT) skills training
Trial: 17664468
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² and cisplatin 75 mg/m² plus fluorouracil 750 mg/m²/d continuous infusion (DCF)
Trial: 17664468
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m² plus fluorouracil 1,000 mg/m²/d continuous infusion (CF)
Trial: 16136167
Drug: 3+7+7 combination
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3+7+7 combination of daunorubicin, Ara‐C, and 6‐thioguanine (DAT)
Trial: 16136167
Drug: High-dose Ara‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Ara‐C during the second induction course
Trial: 16136167
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation chemotherapy
Trial: 16136167
Drug: High-dose Ara‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Ara‐C and multidrug resistance modulator cyclosporine
Trial: 10426601
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone sodium phosphate (0.25 mg/kg)
Trial: 6576814
Drug: Immunotherapy (I)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (I)
Trial: 27132696
Drug: Methotrexate 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3.5 g/m² on day 1 plus cytarabine 2 g/m² twice daily on days 2 and 3 (group A)
Trial: 27132696
Drug: Methotrexate-cytarabine plus
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate-cytarabine plus rituximab 375 mg/m² on days -5 and 0 (group B)
Trial: 27132696
Drug: Methotrexate-cytarabine-rituximab plus
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate-cytarabine-rituximab plus thiotepa 30 mg/m² on day 4 (group C)
Trial: 24149580
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous remifentanil analgesia (20 mcg up to 60 mcg, lockout interval 1-2 minutes)
Trial: 24149580
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (0.1% bupivacaine with 2 mcg/mL fentanyl, initiation bolus 15 mL; maintenance bolus 10 mL, lockout interval 20 minutes, basal infusion 5 mL/h)
Trial: 20135168
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (LTV, V(T) 7 ml/kg)
Trial: 20135168
Drug: Traditional tidal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional tidal volume (TTV, V(T) 10 ml/kg)
Trial: 11919241
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Trial: 11919241
Drug: Bleomycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (30 units over 24 hours on day 1) followed by cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Trial: 8522468
Drug: Trovafloxacin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin 30 mg